NP Central - Continuing Education


Frequent Heartburn:
An Evidence-Based Approach to Cost-Effective Management

References

  1. National Heartburn Alliance. Heartburn overview. Available at: www.heartburnalliance.org.
  2. Johnsson F, Weywadt L, Solhaug JH, et al. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol. 1999;33:15-20.
  3. National Omnibus Study 2003#US035247. Data on file.
  4. The Gallup Organization. A Gallup Survey on Heartburn Across America. Princeton, NJ; 1988.
  5. Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112(5):1448-1456.
  6. El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology. 2004;126(7):1692-1699.
  7. Oliveria SA, Christos PJ, Talley NJ, Dannenberg AJ. Heartburn risk factors, knowledge, and prevention strategies: a population-based survey of individuals with heartburn. Arch Intern Med. 1999;159(14):1592-1598.
  8. Yankelovich Partners = 507 FBH. Data on file.
  9. The Gallup Organization. A Gallup Survey on Heartburn Across America. Princeton, NJ; May 1, 2000.
  10. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med. 1998;104(3):252-258.
  11. Scott M, Gelhot AR. Gastroesophageal reflux disease: diagnosis and management. Am Fam Physician. 1999;59(5):1161-1169.
  12. Locke GR 3rd, Talley NJ, Fett SL, Risk factors associated with symptoms of gastroesophageal reflux. Am J Med. 1999;106(6):642-649.
  13. Cameron AJ, Lagergren J, Henriksson C, et al. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology. 2002;122(1):55-59.
  14. Nilsson M, Johnsen R, Ye W, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA. 2003;290(1):66-72.
  15. Katz PO. Treatment of gastroesophageal reflux disease: use of algorithms to aid in management. Am J Gastroenterol. 1999;94:S3-S10.
  16. Szarka LA, Locke GR. Practical pointers for grappling with GERD. Heartburn gnaws at quality of life for many patients. Postgrad Med. 1999;105:88-90, 95-98, 103-106.
  17. Katzka D. Treatment of GERD: lifestyle modifications. Pract Gastroenterol. 2000;14-31.
  18. DeMeester TR, Wang CI, Wernly JA, et al. Technique, indications, and clinical use of 24 hour esophageal monitoring. J Thorac Cardiovasc Surg. 1980;79:656-670.
  19. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003;98(3 suppl):S2-S7.
  20. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease-current concepts and dilemmas. Am J Gastroenterol. 2001;96(2):303-314.
  21. Heartburn. University of Pittsburgh Medical Center website. Available at: gerd.upmc.com/Diagnosis.htm.
  22. Havelund T, Laursen LS, Lauritsen K. Efficacy of omeprazole in lower grades of gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl. 1994;201:69-73.
  23. Kahrilas P. Clinical manifestations and diagnosis of esophageal reflux. UptoDate. Available at: www.utdol.com/application/topic.asp?file=esophdis/4448&type=A&selectedTitle=3~88.
  24. DeVault KR, Castell DO, and the Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Guidelines. 1999;94(6):1434-1442.
  25. Zuber TJ. Gastroesophageal reflux disease: diagnosis and medical management. CME Bulletin. 2003;2(5).
  26. Dent J, Brun J, Fendrick M, et al. A evidence-based appraisal of reflux disease management-the Genval Workshop Report. Gut. 1999;44(suppl 2):S1-S6.
  27. DeVault KR. Estraesophageal symptoms of GERD. Cleve Clin J Med. 2003;70(suppl 5):S20=S32.
  28. American Gastroenterological Association medical position statement: guidelines on the use of esophageal pH recording. Gastroenterology. 1996;110:1981.
  29. University of Michigan Health System. Management of Gastroesophageal Reflux Disease (GERD). Ann Arbor, Mich: University of Michigan Health System; 2002.
  30. Heidelbaugh JJ, Nostrant TT, Kim C, Van Harrison R. Management of gastroesophageal reflux disease. Am Fam Physician. 2003;68(7):1311-1318.
  31. Decktor DL, Robinson M, Maton PN, et al. Effects of aluminum/magnesium hydroxide and calcium carbonate on esophageal and gastric pH in subjects with heartburn. Am J Ther. 1995;2(8):546-552.
  32. Decktor DL, Robinson M, Gottlieb S. Comparative effects of liquid antacids on esophageal and gastric pH in patients with heartburn. Am J Ther. 1995;2(7):481-486.
  33. P&G MRD#US972782. Data on file.
  34. P&G MRD#US011624. Data on file.
  35. www.endowsec.com/pated/tempo.htm.
  36. Feldman M. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid: a randomized controlled trial. JAMA. 1996;275:1428-1431.
  37. Ciociola AA, Pappa KA, Sirgo MA. Nonprescription doses of ranitidine are effective in the relief of episodic heartburn. Am J Ther. 2001;8:399-408.
  38. Simon TJ, Berlin RG, Gardner AH, et al. Self-directed treatment of intermittent heartburn: a randomized, multicenter, double-blind, placebo-controlled evaluation of antacid and low doses of an H(2)-receptor antagonist (famotidine). Am J Ther. 1995;2:304-313.
  39. Paul K, Redman CM, Chen M. Effectiveness and safety of Nizatidine, 75 mg, for the relief of episodic heartburn. Aliment Pharmacol Ther. 2001;15:1571-1577.
  40. Galmiche JP, Shi G, Simon B, et al. On-demand treatment of gastro-oesophageal reflux symptoms: a comparison of ranitidine 75 mg with cimetidine 200 mg or placebo. Aliment Pharmacol Ther. 1998;12:909-917.
  41. Spiegel JE, Thoden WR, Pappas K, et al. A double-blind, placebo-controlled study of the effectiveness and safety of Nizatidine in the prevention of postprandial heartburn. Arch Intern Med. 1997;157:1594-1599.
  42. Pappa KA, Williams BO, Payne JE, et al. A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn. Aliment Pharmacol Ther. 1999;13:467-473.
  43. Berardi RR. Heartburn self-treatment: focus on nonprescription omeprazole. Rx Consultant. 2004;13:1-8.
  44. Katz O, Sachs G. Mechanism of action and safety of heartburn therapies. Pract Gastroenterology. 2003:80-88.
  45. Over-the-counter omeprazole (Prilosec OTC). Med Lett Drugs Ther. 2003;45(1162):61-62.
  46. Richter JE, Peura D, Benjamin SB, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med. 2000;160(12):1810-1816.
  47. Data on file at AZLP.
  48. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000;40(1):52-62.
  49. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm. 1999;56(23 suppl 4):S11-S17.
  50. Wolfe MM. Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders. UpToDate. Available at: www.utdol.com/application/topic.asp?file=acidpep/10094&type=A&selectedTitle=1~51.
  51. Letter from Janssen Pharmaceutica Research Foundation to healthcare professionals. Available at: www.fda.gov/medwatch/SAFETY/2000/propul.htm.
  52. Bate CM, Keeling PW, O'Morain C, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut. 1990;31(9):968-972.
  53. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798-1810.
  54. Bardhan KD, Muller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ. 1999;318(7182):502-507.
  55. Festen HP, Schenk E, Tan G, et al. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group. Am J Gastroenterol. 1999;94(4):931-936.
  56. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
  57. Sridhar S, Huang J, O'Brien BJ, Hunt RH. Clinical economics review: cost-effectiveness of treatment alternatives for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1996;10(6):865-873.
  58. Gerson LB, Robbins AS, Garber A, et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol. 2000;95(2):395-407.
  59. Heudebert GR, Centor RM, Klapow JC, et al. What is heartburn worth? A cost-utility analysis of management strategies. J Gen Intern Med. 2000;15(3):175-182.
  60. Ofman JJ, Dorn GH, Fennerty MB, Fass R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16(2):261-273.
  61. Bardhan KD. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003;98(3 suppl):S40-S48.
  62. Ofman JJ. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003;98(3 suppl):S8-S14.
  63. Tobin RW, Pope CE II, Greenburg DL. Heartburn and regurgitation. Available at: www.uwgi.org/cme/cmeCourseCD/ch_03/ch03txt.htm.


NP Central
10024 S.E. 240th St., Suite #102, Kent, WA 98031
Phone: 253.852.9042 Fax: 253.852.7725
info@npcentral.net
NP Central Gateway http://www.npcentral.net/